Global End Stage Renal Disease Market: By Treatment, Region-Market Size, Industry Dynamics, Companies, Technology, Opportunity Analysis and Forecast for 2026-2035

Description

The global End Stage Renal Disease (ESRD) market is experiencing significant and sustained growth, reflecting the increasing burden of kidney-related health issues worldwide. In 2025, the market was valued at approximately USD 152.64 billion, and projections indicate a remarkable expansion to USD 573.86 billion by 2035. This represents a compound annual growth rate (CAGR) of 14.16% over the forecast period from 2026 to 2035, underscoring the rapid pace at which the ESRD market is evolving and expanding.

Several factors are driving this robust growth. One of the primary contributors is the rising prevalence of chronic conditions such as diabetes and hypertension, which are the leading causes of ESRD. As these diseases become more common globally, the number of patients requiring dialysis and other renal replacement therapies continues to grow. Additionally, demographic shifts, particularly aging populations in many regions, are increasing the demand for ESRD treatments, as older individuals are more susceptible to kidney failure and related complications.

Noteworthy Market Developments

In the global end stage renal disease (ESRD) market, two companies stand out as the dominant players shaping the industry landscape: Fresenius Medical Care (FME) and DaVita. These two entities effectively form a duopoly, each with distinct business models and strategic approaches that have allowed them to secure and maintain leading positions in this highly specialized healthcare sector.

Fresenius Medical Care operates with a vertically integrated business model, which means that they manufacture the dialysis machines and equipment used in its own clinics. This integration provides Fresenius with a significant advantage by shielding the company from disruptions in the supply chain, ensuring a steady and reliable flow of essential medical devices for its operations.

On the other hand, DaVita has chosen to focus exclusively on service delivery rather than manufacturing. Their core strength lies in operating dialysis clinics and managing patient care, which allows them to concentrate resources on providing high-quality services rather than device production. DaVita's growth strategy is characterized by aggressive international mergers and acquisitions (M&A), enabling rapid expansion into new markets. This approach has proven particularly effective in regions such as Latin America, where they have established a strong presence in countries like Brazil and Colombia.

Core Growth Drivers

The primary factor driving the growth of the end stage renal disease (ESRD) market is the steadily increasing prevalence of Type 2 Diabetes Mellitus and Hypertension worldwide. These two chronic conditions are major contributors to kidney damage, ultimately leading to ESRD. The alarming rise in the number of individuals affected by diabetes, in particular, has been a significant concern for healthcare professionals and researchers alike. Recent estimates from the International Diabetes Federation (IDF) reveal that around 537 million adults are currently living with diabetes globally. This number is expected to surge dramatically, reaching approximately 643 million by the year 2030, reflecting the ongoing global health challenge posed by this metabolic disorder.

Emerging Opportunity Trends

The development of wearable artificial kidneys and advancements in low-maintenance dialysis machines represent promising emerging opportunities that could significantly drive market growth in the coming years. Wearable artificial kidneys, in particular, are poised to revolutionize the treatment landscape by offering patients greater mobility and freedom compared to traditional dialysis methods. These compact, portable devices aim to continuously perform the essential functions of filtering waste and excess fluids from the blood, allowing patients to receive treatment throughout their daily activities without being tethered to bulky, stationary machines. This innovation not only has the potential to improve patients' quality of life but also to reduce the frequency of hospital visits and associated healthcare costs.

Barriers to Optimization

The long-term care required for both dialysis and transplantation involves substantial financial costs, which can place a heavy burden on patients as well as healthcare systems. Dialysis, while life-sustaining, demands ongoing treatments multiple times a week, often for the remainder of a patient's life if a transplant is not available. These repeated sessions, along with the associated medical monitoring, medications, and potential complications, accumulate into significant expenses over time. For many patients, especially those without comprehensive insurance coverage or in regions with limited healthcare funding, the cost can be prohibitive, leading to challenges in accessing or maintaining consistent treatment.

Detailed Market Segmentation

Based on Treatment, dialysis has firmly established itself as the most widely sought-after treatment option for patients with end-stage organ failure, commanding a dominant market share of 81.23%. This overwhelming preference for dialysis stems from its critical role as a life-sustaining therapy for individuals whose organ function has deteriorated to the point where it can no longer support their basic physiological needs. Dialysis effectively performs the essential functions of filtering and purifying the blood, thereby compensating for the loss of kidney function and prolonging patients' lives.

Segment Breakdown

By Treatment Type
- Dialysis
Hemodialysis
In-center Hemodialysis
Home Hemodialysis
Peritoneal Dialysis
Continuous Ambulatory Peritoneal Dialysis (CAPD)
Automated Peritoneal Dialysis (APD)
- Kidney Transplantation
Living Donor Transplant
Deceased Donor Transplant
- Conservative Management
By Product Type
- Equipment
Hemodialysis Machines
Peritoneal Dialysis Machines
Water Treatment Systems
Dialysis Monitoring Systems
- Consumables
Dialyzers
Bloodline Sets
Dialysate Solutions
Catheters
AV Fistula Needles
Tubing Systems
- Drugs
Erythropoiesis Stimulating Agents
Phosphate Binders
Vitamin D Analogs
Iron Supplements
Others
- Services
Dialysis Services
Maintenance Services
Telehealth Monitoring
By Age Group
- Pediatric
- Adult
- Geriatric
By End User
- Dialysis Centers
- Hospitals
- Specialty Clinics
- Home Care Settings
By Region
North America
- The U.S.
- Canada
- Mexico
Europe
- Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
- Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia & New Zealand
- ASEAN
Indonesia
Malaysia
Thailand
Singapore
Rest of ASEAN
- Rest of Asia Pacific
Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of MEA
South America
- Argentina
- Brazil
- Rest of South America

Geography Breakdown

Asia Pacific holds a commanding position in the End Stage Renal Disorder (ESRD) market, capturing nearly 37% of the global market share. This dominance can be attributed to several key factors that are unique to the region. One of the primary drivers is the rapidly growing patient population, which is increasing the demand for renal care and related treatments. The region's healthcare systems are also actively responding to this growing burden through aggressive public health interventions aimed at improving diagnosis, management, and treatment outcomes for ESRD patients.

The Asia Pacific region faces a complex and dual challenge in managing the ESRD burden. On one hand, developed countries such as Japan are grappling with aging populations, which naturally lead to higher incidences of chronic conditions like renal failure. On the other hand, emerging economies within the region are experiencing a significant rise in diabetic nephropathy, a complication of diabetes that often progresses to ESRD. This rising tide of diabetes-driven kidney disease is putting additional strain on healthcare resources and necessitating tailored strategies to address the unique needs of these diverse populations.

Leading Market Participants

Cantel Medical
Asahi Kasei Medical Co., Ltd.
B. Braun Melsungen AG
Baxter International, Inc.
AngioDynamics, Inc.
Becton Dickinson and Company
DaVita Inc.
U.S. Renal Care, Inc.
JMS Co. Ltd.
Medtronic Plc
Nikkiso Co., Ltd.
Fresenius Medical Care AG & Co. KGaA
Nipro Corporation
Teleflex Incorporated
Toray Industries Inc.
Other Prominent Players

Product Code: AA02261697

Table of Content

Chapter 1. Executive Summary: Global End Stage Renal Disease Market

Chapter 2. Research Methodology & Research Framework

2.1. Research Objective
2.2. Product Overview
2.3. Market Segmentation
2.4. Qualitative Research
- 2.4.1. Primary & Secondary Sources
2.5. Quantitative Research
- 2.5.1. Primary & Secondary Sources
2.6. Breakdown of Primary Research Respondents, By Region
2.7. Assumption for Study
2.8. Market Size Estimation
2.9. Data Triangulation

Chapter 3. Global End Stage Renal Disease Market Overview

3.1. Industry Value Chain Analysis
- 3.1.1. Raw Material Suppliers
- 3.1.2. Manufacturers
- 3.1.3. Distributors
- 3.1.4. End User
3.2. Industry Outlook
- 3.2.1. Nine Kidney Disease Research Breakthroughs from 2023
- 3.2.2. Overview of End Stage Renal Disease Drugs Pipeline
- 3.2.3. Annual Treatment Cost of End Stage Renal Disease
- 3.2.4. Epidemiology of End Stage Renal Disease
- 3.2.5. Case Study Analysis
  - 3.2.5.1. Chronic Kidney Disease and the Global Public Health Agenda: An International Consensus
  - 3.2.5.2. Management of Chronic Kidney Disease: The Current Novel and Forgotten Therapies
3.3. PESTLE Analysis
3.4. Porter's Five Forces Analysis
- 3.4.1. Bargaining Power of Suppliers
- 3.4.2. Bargaining Power of Buyers
- 3.4.3. Threat of Substitutes
- 3.4.4. Threat of New Entrants
- 3.4.5. Degree of Competition
3.5. Market Growth and Outlook
- 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
- 3.5.2. Price Trend Analysis

Chapter 4. Global End Stage Renal Disease Market Analysis

4.1. Competition Dashboard
- 4.1.1. Market Concentration Rate
- 4.1.2. Company Market Share Analysis (Value %), 2025
- 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global End Stage Renal Disease Market Analysis

5.1. Market Dynamics and Trends
- 5.1.1. Growth Drivers
- 5.1.2. Restraints
- 5.1.3. Opportunity
- 5.1.4. Key Trends
5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 5.2.1. By Treatment Type
  - 5.2.1.1. Key Insights
    - 5.2.1.1.1. Dialysis
      - 5.2.1.1.1.1. Hemodialysis
        
        5.2.1.1.1.1.1. In-center Hemodialysis
        5.2.1.1.1.1.2. Home Hemodialysis
      - 5.2.1.1.1.2. Peritoneal Dialysis
      - 5.2.1.1.1.3. Continuous Ambulatory Peritoneal Dialysis (CAPD)
      - 5.2.1.1.1.4. Automated Peritoneal Dialysis (APD)
    - 5.2.1.1.2. Kidney Transplantation
      - 5.2.1.1.2.1. Living Donor Transplant
      - 5.2.1.1.2.2. Deceased Donor Transplant
    - 5.2.1.1.3. Conservative Management
- 5.2.2. By Product Type
  - 5.2.2.1. Key Insights
    - 5.2.2.1.1. Equipment
      - 5.2.2.1.1.1. Hemodialysis Machines
      - 5.2.2.1.1.2. Peritoneal Dialysis Machines
      - 5.2.2.1.1.3. Water Treatment Systems
      - 5.2.2.1.1.4. Dialysis Monitoring Systems
    - 5.2.2.1.2. Consumables
      - 5.2.2.1.2.1. Dialyzers
      - 5.2.2.1.2.2. Bloodline Sets
      - 5.2.2.1.2.3. Dialysate Solutions
      - 5.2.2.1.2.4. Catheters
      - 5.2.2.1.2.5. AV Fistula Needles
      - 5.2.2.1.2.6. Tubing Systems
    - 5.2.2.1.3. Drugs
      - 5.2.2.1.3.1. Erythropoiesis Stimulating Agents
      - 5.2.2.1.3.2. Phosphate Binders
      - 5.2.2.1.3.3. Vitamin D Analogs
      - 5.2.2.1.3.4. Iron Supplements
      - 5.2.2.1.3.5. Others
    - 5.2.2.1.4. Services
      - 5.2.2.1.4.1. Dialysis Services
      - 5.2.2.1.4.2. Maintenance Services
      - 5.2.2.1.4.3. Telehealth Monitoring
- 5.2.3. By Age Group
  - 5.2.3.1. Key Insights
    - 5.2.3.1.1. Pediatric
    - 5.2.3.1.2. Adult
    - 5.2.3.1.3. Geriatric
- 5.2.4. By End User
  - 5.2.4.1. Key Insights
    - 5.2.4.1.1. Dialysis Centers
    - 5.2.4.1.2. Hospitals
    - 5.2.4.1.3. Specialty Clinics
    - 5.2.4.1.4. Home Care Settings
- 5.2.5. By Region
  - 5.2.5.1. Key Insights
    - 5.2.5.1.1. North America
      - 5.2.5.1.1.1. The U.S.
      - 5.2.5.1.1.2. Canada
      - 5.2.5.1.1.3. Mexico
    - 5.2.5.1.2. Europe
      - 5.2.5.1.2.1. Western Europe
        
        5.2.5.1.2.1.1. The UK
        5.2.5.1.2.1.2. Germany
        5.2.5.1.2.1.3. France
        5.2.5.1.2.1.4. Italy
        5.2.5.1.2.1.5. Spain
        5.2.5.1.2.1.6. Rest of Western Europe
      - 5.2.5.1.2.2. Eastern Europe
        
        5.2.5.1.2.2.1. Poland
        5.2.5.1.2.2.2. Russia
        5.2.5.1.2.2.3. Rest of Eastern Europe
    - 5.2.5.1.3. Asia Pacific
      - 5.2.5.1.3.1. China
      - 5.2.5.1.3.2. India
      - 5.2.5.1.3.3. Japan
      - 5.2.5.1.3.4. South Korea
      - 5.2.5.1.3.5. Australia & New Zealand
      - 5.2.5.1.3.6. ASEAN
        
        5.2.5.1.3.6.1. Indonesia
        5.2.5.1.3.6.2. Malaysia
        5.2.5.1.3.6.3. Thailand
        5.2.5.1.3.6.4. Singapore
        5.2.5.1.3.6.5. Rest of ASEAN
      - 5.2.5.1.3.7. Rest of Asia Pacific
    - 5.2.5.1.4. Middle East & Africa
      - 5.2.5.1.4.1. UAE
      - 5.2.5.1.4.2. Saudi Arabia
      - 5.2.5.1.4.3. South Africa
      - 5.2.5.1.4.4. Rest of MEA
    - 5.2.5.1.5. South America
      - 5.2.5.1.5.1. Argentina
      - 5.2.5.1.5.2. Brazil
      - 5.2.5.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

6.1. Market Dynamics and Trends
- 6.1.1. Growth Drivers
- 6.1.2. Restraints
- 6.1.3. Opportunity
- 6.1.4. Key Trends
6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 6.2.1. Key Insights
  - 6.2.1.1. By Treatment Type
  - 6.2.1.2. By Product Type
  - 6.2.1.3. By Age Group
  - 6.2.1.4. By End User
  - 6.2.1.5. By Country

Chapter 7. Europe Market Analysis

7.1. Market Dynamics and Trends
- 7.1.1. Growth Drivers
- 7.1.2. Restraints
- 7.1.3. Opportunity
- 7.1.4. Key Trends
7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 7.2.1. Key Insights
  - 7.2.1.1. By Treatment Type
  - 7.2.1.2. By Product Type
  - 7.2.1.3. By Age Group
  - 7.2.1.4. By End User
  - 7.2.1.5. By Country

Chapter 8. Asia Pacific Market Analysis

8.1. Market Dynamics and Trends
- 8.1.1. Growth Drivers
- 8.1.2. Restraints
- 8.1.3. Opportunity
- 8.1.4. Key Trends
8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 8.2.1. Key Insights
  - 8.2.1.1. By Treatment Type
  - 8.2.1.2. By Product Type
  - 8.2.1.3. By Age Group
  - 8.2.1.4. By End User
  - 8.2.1.5. By Country

Chapter 9. Middle East & Africa Market Analysis

9.1. Market Dynamics and Trends
- 9.1.1. Growth Drivers
- 9.1.2. Restraints
- 9.1.3. Opportunity
- 9.1.4. Key Trends
9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 9.2.1. Key Insights
  - 9.2.1.1. By Treatment Type
  - 9.2.1.2. By Product Type
  - 9.2.1.3. By Age Group
  - 9.2.1.4. By End User
  - 9.2.1.5. By Country

Chapter 10. South America Market Analysis

10.1. Market Dynamics and Trends
- 10.1.1. Growth Drivers
- 10.1.2. Restraints
- 10.1.3. Opportunity
- 10.1.4. Key Trends
10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 10.2.1. Key Insights
  - 10.2.1.1. By Treatment Type
  - 10.2.1.2. By Product Type
  - 10.2.1.3. By Age Group
  - 10.2.1.4. By End User
  - 10.2.1.5. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

11.1. Cantel Medical
11.2. Asahi Kasei Medical Co., Ltd.
11.3. B. Braun Melsungen AG
11.4. Baxter International, Inc.
11.5. AngioDynamics, Inc.
11.6. Becton Dickinson and Company
11.7. DaVita Inc.
11.8. U.S. Renal Care, Inc.
11.9. JMS Co. Ltd.
11.10. Medtronic Plc
11.11. Nikkiso Co., Ltd.
11.12. Fresenius Medical Care AG & Co. KGaA
11.13. Nipro Corporation
11.14. Teleflex Incorporated
11.15. Toray Industries Inc.
11.16. Other Prominent Players

Chapter 12. Annexure

12.1. List of Secondary Sources
12.2. Key Country Markets- Macro Economic Outlook/Indicators